Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.

Binnaz YasarYae-Eun SuhEwan ChapmanLuke NichollsDaniel HendersonCaroline JonesKirsty MorrisonEmma WellsJulia HendersonCarole MeehanAslam SohaibHelen TaylorAlison TreeNicholas van As

Published in: International journal of radiation oncology, biology, physics (2024)

CyberKnife SBRT-delivered dose of 36.25 Gy to the prostate with a simultaneous integrated boost up to 47.5 Gy is well tolerated. Acute and late genitourinary and gastrointestinal toxicity rates are comparable to other contemporary SBRT trials and series with focal boost.

Keyphrases

prostate cancer
radiation therapy
radical prostatectomy
liver failure
respiratory failure
oxidative stress
drug induced
intensive care unit
aortic dissection
metabolic syndrome
skeletal muscle
brain metastases
acute respiratory distress syndrome
glycemic control